Arabic version: لقاح الحمل يقلل بشكل كبير من دخول المستشفيات بسبب RSV للمواليد الجدد

A vaccine administered during pregnancy has resulted in a significant reduction in hospital admissions for newborns suffering from respiratory syncytial virus (RSV), with UK health officials reporting an 80% decrease. This vaccine, offered to pregnant women from 28 weeks of pregnancy, aims to protect babies from severe chest infections caused by RSV, which affects many infants in their early months.

According to BBC News, RSV is a leading cause of hospitalization for babies under one year old, with more than 20,000 cases reported annually in the UK. The virus can lead to serious health issues, including difficulty breathing and feeding. The UK Health Security Agency (UKHSA) has confirmed that the vaccine provides “excellent protection” when administered during the later stages of pregnancy.

The vaccine was introduced in the UK in 2024 following clinical trials that demonstrated its effectiveness in boosting the immune response of pregnant women, allowing them to pass on protection to their newborns through the placenta. A recent study showed that the vaccine offers nearly 85% protection when given at least four weeks prior to delivery, and even some protection remains if administered closer to the birth.

Dr. Conall Watson, the national program lead for RSV at UKHSA, emphasized the importance of timely vaccination for pregnant women, stating that the vaccine can significantly enhance the safety of infants during the winter months. Current data indicates that approximately 64% of pregnant women in England receive the RSV vaccine, although this figure drops to 53% in London.

The vaccine’s introduction is seen as a crucial step in reducing the risk of RSV-related hospitalizations among newborns. Health officials continue to encourage pregnant women to consult with healthcare professionals regarding the vaccine to ensure the best outcomes for their children.